Non-representative sampling detected during internal audit – CAPA to prevent recurrence


Published on 26/04/2026

Identifying and Resolving Non-Representative Sampling Issues in Pharmaceutical Manufacturing

In the highly regulated pharmaceutical manufacturing environment, maintaining the integrity of raw materials is critical. A recent internal audit revealed a significant issue related to non-representative sampling, bringing into question the supplier’s control measures. Understanding the implications of non-representative sampling and effectively addressing this issue is essential for compliance with Good Manufacturing Practice (GMP) regulations. This article guides you through a detailed investigation framework to help professionals identify the root cause of sampling errors and implement effective Corrective and Preventive Actions (CAPA).

By the end of this article, you will have a structured approach to evaluate signals from the production floor, determine likely causes of sampling discrepancies, and design robust CAPA strategies aimed at preventing future occurrences. Let us proceed with a thorough and systematic investigation of this critical issue.

Symptoms/Signals on the Floor or in the Lab

Non-representative sampling can manifest in various ways during production and quality control. Here, we highlight several key symptoms and signals

that warrant immediate attention:

  • Inconsistent Quality Control Results: Variability in test results for raw materials received from suppliers, where some samples fail to meet specification while others do not, indicating potential sampling errors.
  • Unexpected Batch Failures: A rise in the number of Out of Specification (OOS) results linked to analytical testing of incoming raw materials may signal issues with sampling techniques.
  • Supplier Audit Findings: Documented observations from supplier audits or internal assessments that note deviations in the sampling techniques versus documented procedures.
  • Material Discrepancies: Notable differences in physical attributes of materials, such as color or particle size, as reported by production staff or analytical labs, suggesting non-representative sampling at delivery.

These signals can prompt further investigation into the sampling practices as well as an assessment of vendor qualification processes.

Likely Causes (by category: Materials, Method, Machine, Man, Measurement, Environment)

Understanding potential causes is crucial in the path towards identifying root issues in non-representative sampling. Below are likely causes organized by category:

Category Likely Causes
Materials Deteriorated storage conditions, expired shelf life, contamination, variability in raw material properties.
Method Inadequate sampling methodology, lack of standard operating procedures (SOPs) providing clear guidelines for representative sampling.
Machine Faulty or uncalibrated sampling equipment leading to biased sample collection.
Man Inadequate training of personnel responsible for sampling, procedural errors due to misunderstanding SOPs.
Measurement Errors in analytical measurement techniques that could skew results related to representative samples.
Environment Improper storage conditions (temperature, humidity) affecting material integrity and hence sampling representativeness.
Pharma Tip:  Improper sample storage during supplier complaint review – CAPA to prevent recurrence

By categorizing causes into these sections, we adopt a systematic approach to identify the most likely factors contributing to the non-representative sampling issue.

Immediate Containment Actions (first 60 minutes)

When non-representative sampling is identified, it is critical to act quickly to contain the issue. Immediate containment actions include:

  1. Stop Further Processing: Halt production and quarantine affected batches to prevent contaminated or nonrepresentative materials from being utilized.
  2. Notify QA: Alert the Quality Assurance team to initiate an investigation and establish an internal communication chain to inform relevant stakeholders.
  3. Review Recent Sampling and Analytical Data: Collect all related sampling and testing data quickly to assess the scope of the problem and identify potentially impacted batches.
  4. Document Initial Findings: Begin documenting the incident immediately, including time, personnel involved, and conditions at the time of the sampling to support thorough investigation.
  5. Conduct an Initial Risk Assessment: Evaluate the potential risk to product quality and patient safety based on the sampling issue and gather preliminary evidence for further investigation.

These immediate actions will help contain the problem and begin to outline the extent of non-representative sampling effects on product quality.

Investigation Workflow (data to collect + how to interpret)

The investigation into non-representative sampling should follow a structured workflow. Here are practical steps to ensure a thorough investigation:

  • Define the Scope of Investigation: Clearly articulate the objective of the investigation and identify affected materials, batches, and samples.
  • Gather Relevant Data: Collect documentation including batch records, sampling procedures, supplier audit results, employee training records, and environmental monitoring logs.
  • Interview Key Personnel: Engage employees involved in the sampling process to understand their practices, challenges, and observations while conducting the sampling.
  • Review SOP Compliance: Assess adherence to established sampling SOPs and any deviations noted during the process.
  • Perform Trend Analysis: Analyze historical data to determine if similar issues have been observed in the past, and if so, evaluate how they were managed.

The collected data should be analyzed in conjunction with the symptoms observed, and initial hypotheses formed regarding the causes. This thorough approach helps eliminate improper conclusions and narrows down towards potential root causes of the non-representative sampling.

Root Cause Tools (5-Why, Fishbone, Fault Tree) and when to use which

Using root cause analysis tools effectively can help elucidate the underlying factors contributing to non-representative sampling. Here’s a breakdown of suitable tools:

  • 5-Why Analysis: This technique helps to drill down to the fundamental cause of a problem by iteratively asking “why” at least five times. Utilize this method when clearly identified symptoms lead to confusing causes that require clarity.
  • Fishbone Diagram (Ishikawa): This visual tool categorizes potential causes into six major categories (Materials, Method, Machine, Man, Measurement, Environment) and is useful when brainstorming during team discussions.
  • Fault Tree Analysis: A more complex technical method for analyzing the chains of events leading to failures. It’s best suited for difficult cases where a systematic breakdown of events is needed to determine all possible failure modes.
Pharma Tip:  Sampling plan not risk-based during internal audit – CAPA to prevent recurrence

Select the applicable tools based on the complexity of investigation and the specificity of symptoms observed, ensuring a comprehensive understanding of issues related to non-representative sampling.

CAPA Strategy (correction, corrective action, preventive action)

Implementing a robust CAPA strategy is essential for addressing non-representative sampling accurately and effectively. Here’s how to formulate your CAPA:

  • Correction: Address immediate issues by rerunning affected tests on newly collected representative samples and ensuring non-compliance areas are effectively managed.
  • Corrective Actions: Modify SOPs to enhance clarity on sampling techniques. Offer additional training to employees involved in sampling and ensure equipment is correctly calibrated before use.
  • Preventive Actions: Establish a monitoring system to routinely assess compliance with sampling practices. Conduct quarterly audits and establish supplier qualifications to consistently evaluate the reliability of material sources.

Document all stages of CAPA meticulously to demonstrate compliance and serve as evidence during regulatory inspections.

Control Strategy & Monitoring (SPC/trending, sampling, alarms, verification)

A well-defined control strategy is vital for ensuring the ongoing effectiveness of measures implemented to address non-representative sampling. Consider the following:

  • Statistical Process Control (SPC): Use SPC charts to monitor trends in sampling and testing results over time to ensure that variability is within acceptable bounds.
  • Regular Sampling Protocols: Develop a schedule for regular sampling from each identified critical material batch to reinforce routine checks on material quality.
  • Alarms and Alerts: Implement alarm systems for identifying deviations in sampling techniques or batch variability during production processes.
  • Verification Procedures: Establish robust verification methods to ensure that sampling compliance is consistently observed. This could include physical audits and review of the generated data.

Validation / Re-qualification / Change Control impact (when needed)

Changes made in response to non-representative sampling must be incorporated into validation and change control processes. Important considerations include:

Related Reads

  • Impact Assessment: Review how changes to sampling processes or SOP adjustments might influence existing validations or the need for re-qualification of affected processes.
  • Documentation: Ensure thorough documentation of any validation changes, including rationale, methodology, and results, to maintain compliance with regulatory standards.
  • Training Updates: Implement updated training programs reflecting revised SOPs, ensuring personnel are qualified to operate under the new guidelines.

By maintaining rigorous change control measures, companies can ensure continual compliance and uphold product integrity.

Pharma Tip:  Sampling SOP not followed during supplier complaint review – preventing false OOS results

Inspection Readiness: what evidence to show (records, logs, batch docs, deviations)

Maintaining inspection readiness is critical for avoiding regulatory penalties. During an inspection following an incident of non-representative sampling, ensure that you can produce:

  • Batch Production Records: Documented details on the production of any batches that utilized the questionable samples.
  • Sampling SOPs: Current and previous versions of sampling standard operating procedures demonstrating compliance and any changes made.
  • Deviation Reports: Entries for any identified deviations, including non-conformances related to sampling processes and subsequent investigations.
  • Corrective Action Documentation: Evidence of corrective actions taken, showing how the root causes of non-compliance have been addressed and how future incidents will be prevented.

Having organized documentation ready for regulatory review can ease scrutiny and reinforce a company’s commitment to maintaining high quality, compliant manufacturing practices.

FAQs

What is non-representative sampling?

Non-representative sampling refers to sampling methods that do not accurately reflect the characteristics of the entire batch of material, leading to potential quality issues.

How can I identify issues with non-representative sampling?

Look for inconsistent test results, unexpected failures, and discrepancies in material attributes reported by analytical labs or production staff.

What are the main causes of non-representative sampling?

Common causes include inadequate sampling procedures, personnel training gaps, improper storage conditions, or equipment errors.

What should immediate containment actions include?

Immediate actions involve halting production, notifying quality assurance, reviewing sampling data, and documenting initial findings rapidly.

What tools are best for root cause analysis?

5-Why Analysis, Fishbone Diagrams, and Fault Tree Analysis are effective tools for identifying root causes of non-representative sampling.

How do I implement effective CAPA strategies?

Develop CAPA strategies encompassing immediate corrections, corrective actions addressing root causes, and preventive actions to avert future occurrences.

What role does statistical process control play?

SPC helps monitor the sampling process over time to identify trends and ensure ongoing compliance with established quality standards.

How do changes in protocols affect validations?

Changes necessitate rigorous assessment to ensure that validations remain applicable, covering all aspects of the revised protocols.

What documentation is required for inspection readiness?

Documentation should include batch records, SOPs, deviation reports, and records of corrective actions taken.

How can I ensure continuous improvement in sampling procedures?

Engage in regular audits, provide ongoing training for personnel, and maintain open communication regarding best practices and compliance requirements.

What steps can I take for effective supplier qualification?

Create a thorough vendor qualification process encompassing audits, material assessments, and continuous monitoring of suppliers’ practices.

What is the significance of monitoring environmental conditions during sampling?

Monitoring ensures that raw materials are stored under conditions that maintain their integrity, thereby supporting representative sampling.